Imiquimod 5%/Diclofenac Sodium 1% Topical Cream is a compounded formulation designed to treat a range of skin conditions. This includes Actinic Keratosis, Basal Cell Carcinoma, Bowen's Disease, Squamous Cell Carcinoma, and Molluscum Contagiosum. The cream is a semisolid preparation dispensed in a pump mechanism, which allows for convenient and controlled application on the skin for localized treatment or absorption of active ingredients.

The cream contains two active ingredients: Imiquimod and Diclofenac Sodium. Imiquimod is an immune response modifier that stimulates the body's own immune system to combat the skin condition. On the other hand, Diclofenac Sodium is an anti-inflammatory that aids in reducing inflammation and pain associated with the skin condition. When used in combination, these two ingredients can provide an effective treatment for the aforementioned skin conditions.

It is crucial to follow your healthcare provider's instructions when using Imiquimod 5%/Diclofenac Sodium 1% Topical Cream. Common side effects may include redness, itching, burning, and irritation at the application site. If you experience any severe side effects, it is important to contact your healthcare provider immediately.

At Bayview Pharmacy, we are dedicated to providing our patients with the highest quality of care. If you have any questions about Imiquimod 5%/Diclofenac Sodium 1% Topical Cream or any other medications, please do not hesitate to reach out to us. We are here to assist you with your healthcare needs.

Imiquimod 5%/Diclofenac Sodium 1% Topical Cream is a compounded formulation designed for the treatment of various skin conditions including actinic keratosis, basal cell carcinoma, Bowen's disease, squamous cell carcinoma, and molluscum contagiosum. This cream combines the potent effects of Imiquimod, an immune response modifier, and Diclofenac Sodium, a nonsteroidal anti-inflammatory drug (NSAID).

Imiquimod works by stimulating the body's own immune system to combat the virus that causes molluscum contagiosum. On the other hand, Diclofenac Sodium reduces inflammation and pain. When used in combination, these two active ingredients can effectively reduce the size and number of lesions caused by the aforementioned skin conditions.

The cream is dispensed in a pump mechanism, which allows for convenient and controlled application on the skin. It is designed for localized treatment, ensuring that the active ingredients are absorbed precisely where they are needed. Patients are advised to apply the cream to the affected area twice daily for a period of up to 16 weeks.

It is crucial to avoid applying the cream on broken or irritated skin. Additionally, contact with the eyes, nose, and mouth should be avoided. Common side effects of Imiquimod 5%/Diclofenac Sodium 1% Topical Cream include redness, itching, burning, and irritation at the application site. If any of these side effects occur, patients are advised to contact their healthcare provider immediately.

Imiquimod 5%/Diclofenac Sodium 1% Topical Cream is a powerful tool in the treatment of various skin conditions. However, it is important to use it as directed by a healthcare provider to ensure its effectiveness and safety.

Imiquimod 5%/Diclofenac Sodium 1% Topical Cream is a compounded formulation that combines the therapeutic benefits of two active ingredients, Imiquimod and Diclofenac Sodium, to treat a range of skin conditions. This topical cream is dispensed in a pump mechanism for easy and controlled application directly on the affected skin area.

Imiquimod, an immune response modifier, stimulates the body's immune system to combat infections or diseases. It is particularly effective in treating skin conditions caused by sun damage or viral infections. Diclofenac Sodium, a non-steroidal anti-inflammatory drug (NSAID), complements the action of Imiquimod by reducing inflammation and pain associated with these conditions.

The combined action of these two ingredients makes this topical cream an effective treatment for Actinic Keratosis, a precancerous skin condition; Basal Cell Carcinoma and Bowen's Disease, types of skin cancer; Squamous Cell Carcinoma, another form of skin cancer; and Molluscum Contagiosum, a viral skin infection. In each of these conditions, the cream works by stimulating the body's immune system to fight the infection and reduce symptoms.

Imiquimod 5%/Diclofenac Sodium 1% Topical Cream is a safe and effective treatment option for these skin conditions. However, it is crucial to use this medication as directed by your healthcare provider. If you have any questions or concerns about the use of this medication, do not hesitate to seek professional advice.

This compounded formulation of Imiquimod 5%/Diclofenac Sodium 1% Topical Cream is a semisolid preparation dispensed in a pump mechanism, designed for convenient and controlled application on the skin. It is primarily used for localized treatment or absorption of active ingredients. This formulation has been effectively used to treat a variety of skin conditions, including Actinic Keratosis, Basal Cell Carcinoma, Bowen's Disease, Squamous Cell Carcinoma, and Molluscum Contagiosum. It has also shown efficacy in treating other skin conditions such as warts, psoriasis, and actinic cheilitis.

Imiquimod 5%/Diclofenac Sodium 1% Topical Cream has been found to be effective in reducing inflammation and promoting healing of the skin. It has also been used to reduce the size of skin lesions and to reduce the risk of scarring. This formulation has been found to be well tolerated and has minimal side effects. However, patients should be aware that this formulation may cause skin irritation, redness, and itching. It may also cause a burning sensation when applied to the skin.

Patients should contact their healthcare provider if they experience any of these side effects. Prescribers should be aware that this formulation should not be used in patients with a known hypersensitivity to either Imiquimod or Diclofenac Sodium. If you have any questions about this formulation, please reach out to your healthcare provider.